Abstract Number: 1825 • 2019 ACR/ARP Annual Meeting
Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis
Background/Purpose: We previously developed a Thrombosis Risk Score, a sum of three factors: lupus anticoagulant (by RVVT confirm); low C3; and C4d bound to platelets.…Abstract Number: 2887 • 2019 ACR/ARP Annual Meeting
Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus
Background/Purpose: Cell-bound complement activation products (CB-CAPs) are stable forms of classical complement activation ex-vivo, with high sensitivity and specificity for systemic lupus erythematosus (SLE). We…Abstract Number: 642 • 2019 ACR/ARP Annual Meeting
Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus
Background/Purpose: Complement components, including C4d, can be detected on the surface of activated platelets and they have been associated with vascular disease in systemic lupus…Abstract Number: 669 • 2019 ACR/ARP Annual Meeting
Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria
Background/Purpose: We reported (Ramsey-Goldman et al., Arthritis Rheumatol 2018: 70 [suppl 10]) that cell-bound complement activation products (CB-CAPs) and a multi-analyte assay panel with algorithm…Abstract Number: 686 • 2019 ACR/ARP Annual Meeting
Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort
Background/Purpose: There is a lack of reliable biomarkers for disease activity in SLE. While C3a, an anaphylatoxin generated during of complement activation, could be predictive…Abstract Number: 931 • 2018 ACR/ARHP Annual Meeting
Patients with Seropositive Rheumatoid Arthritis Who Do Not Mount a CRP Response When They Have Synovitis Are Immunologically Distinct and Are Poorly Served By Current Management Strategies
Background/Purpose: An atypical subgroup of patients with seropositive rheumatoid arthritis (RA) has been identified with confirmed synovitis but normal levels of the acute phase protein…Abstract Number: 1017 • 2018 ACR/ARHP Annual Meeting
Autoantigen Pentraxin-3 Is an Inflammatory Cytokine Storms Suppressor By Switching Monocytes Pyroptosis to Apoptosis in a Complement-Dependent Manner in Rheumatoid Arthritis
Background/Purpose: A delayed diagnoses and therapy of ACPA (Anti cyclic citrullinated peptide antibody)-negative RA patients might be associated with effective serum biomarkers in clinic. Methods:…Abstract Number: 1098 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are autoimmune diseases. The histopathological pattern of skin involvement can be similar, i.e. interface dermatitis, but the…Abstract Number: 1708 • 2018 ACR/ARHP Annual Meeting
Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus
Background/Purpose: Although aberrant complement activation is involved in the pathogenesis of systemic lupus erythematosus (SLE), the role of complement regulatory proteins in disease activity of…Abstract Number: 2030 • 2018 ACR/ARHP Annual Meeting
Patients with Childhood-Onset SLE (cSLE) and Hypertension Have Consistently Higher Serum Concentrations of C3 and C4 Than Those without Hypertension
Background/Purpose: Chronic systemic inflammation, mediated in part by complement, and inadequate vascular repair mechanisms affect patients with cSLE from a young age and are associated…Abstract Number: 670 • 2017 ACR/ARHP Annual Meeting
Membrane Attack Complex (MAC) Deposition in Lupus Nephritis Is Associated with Hypertension and Poor Clinical Response to Treatment
Background/Purpose: LN is characterized by deposition of immune complexes in the kidney. Activation of the classical complement pathway by dsDNA is believed to play a…Abstract Number: 1077 • 2017 ACR/ARHP Annual Meeting
The Lectin Pathway of the Complement System Is Activated in Patients with Systemic Lupus Erythematosus
Background/Purpose: The pathogenesis of Systemic Lupus Erythematosus (SLE) involves complement activation. It is well established that activation of complement through the classical pathway (CP) and…Abstract Number: 1671 • 2017 ACR/ARHP Annual Meeting
Complement C4 Gene Copy Number Variations Bestow Large Ranges of Serum C4 Protein Levels in Chinese Patients with Systemic Lupus Erythematosus (SLE) and Contribute to Organ and Cardiovascular Damages over Time
Background/Purpose: Human SLE is characterized by fluctuating serum levels of complement proteins. There are frequent copy number variations (CNVs) of complement C4A and C4B genes…Abstract Number: 1842 • 2017 ACR/ARHP Annual Meeting
Subsetting Systemic Lupus Erythematosus By Interferon Gene Signatures and Serologies (anti-dsDNA and Low Complement) Uncovers Significant Clinical Diversity
Background/Purpose: Personalized therapy in systemic lupus erythematosus (SLE) will require identifying SLE subsets that will benefit from different targeted therapies. Belimumab, for example, has…Abstract Number: 129 • 2017 Pediatric Rheumatology Symposium
Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »